Knight Stephen R, Oniscu Gabriel C, Devey Luke, Simpson Kenneth J, Wigmore Stephen J, Harrison Ewen M
Scottish Liver Transplant Unit, Royal Infirmary of Edinburgh, Edinburgh, EH16 4SA, United Kingdom.
Pipeline Futures Group, GSK, 1250 South Collegeville Rd, Collegeville, Pennsylvania, 19426, United States of America.
PLoS One. 2016 Mar 1;11(3):e0148782. doi: 10.1371/journal.pone.0148782. eCollection 2016.
Acute kidney injury is associated with a poor prognosis in acute liver failure but little is known of outcomes in patients undergoing transplantation for acute liver failure who require renal replacement therapy.
A retrospective analysis of the United Kingdom Transplant Registry was performed (1 January 2001-31 December 2011) with patient and graft survival determined using Kaplan-Meier methods. Cox proportional hazards models were used together with propensity-score based full matching on renal replacement therapy use.
Three-year patient and graft survival for patients receiving renal replacement therapy were 77.7% and 72.6% compared with 85.1% and 79.4% for those not requiring renal replacement therapy (P<0.001 and P = 0.009 respectively, n = 725). In a Cox proportional hazards model, renal replacement therapy was a predictor of both patient death (hazard ratio (HR) 1.59, 95% CI 1.01-2.50, P = 0.044) but not graft loss (HR 1.39, 95% CI 0.92-2.10, P = 0.114). In groups fully matched on baseline covariates, those not receiving renal replacement therapy with a serum creatinine greater than 175 μmol/L had a significantly worse risk of graft failure than those receiving renal replacement therapy.
In patients being transplanted for acute liver failure, use of renal replacement therapy is a strong predictor of patient death and graft loss. Those not receiving renal replacement therapy with an elevated serum creatinine may be at greater risk of early graft failure than those receiving renal replacement therapy. A low threshold for instituting renal replacement therapy may therefore be beneficial.
急性肾损伤与急性肝衰竭的预后不良相关,但对于因急性肝衰竭接受移植且需要肾脏替代治疗的患者的预后情况,人们知之甚少。
对英国移植登记处进行了回顾性分析(2001年1月1日至2011年12月31日),采用Kaplan-Meier方法确定患者和移植物的生存率。使用Cox比例风险模型,并基于肾脏替代治疗的使用情况进行倾向评分完全匹配。
接受肾脏替代治疗的患者三年生存率分别为77.7%和72.6%,而不需要肾脏替代治疗的患者为85.1%和79.4%(分别为P<0.001和P = 0.009;n = 725)。在Cox比例风险模型中,肾脏替代治疗是患者死亡的预测因素(风险比[HR] 1.59,95%置信区间1.01 - 2.50,P = 0.044),但不是移植物丢失的预测因素(HR 1.39,95%置信区间0.92 - 2.10,P = 0.114)。在根据基线协变量完全匹配的组中,血清肌酐大于175 μmol/L且未接受肾脏替代治疗的患者,其移植物失败风险显著高于接受肾脏替代治疗的患者。
在因急性肝衰竭接受移植的患者中,使用肾脏替代治疗是患者死亡和移植物丢失的有力预测因素。血清肌酐升高但未接受肾脏替代治疗的患者,其早期移植物失败风险可能高于接受肾脏替代治疗的患者。因此,较低的启动肾脏替代治疗阈值可能是有益的。